Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pharmacoeconomic impact of empagliflozin in patients with chronic kidney disease

Background. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of renal failure in patients with chronic kidney disease (CKD). Objective. To evaluate the pharmacoeconomic impact of empagliflozin in patients with CKD. Material and methods. The economic impact of empagliflozin...

D. Kristeleva, I. Dyakov, S. Zyryanov · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.